Isabelle Demeestere

List of Publications by Year
in descending order

100 papers	5,566 citations	87888 38 h-index	82547 72 g-index
105 all docs	105 docs citations	105 times ranked	3780 citing authors

#	Article	IF	Citations
1	Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin's Disease. Oncologist, 2007, 12, 1437-1442.	3.7	346
2	Live birth after autograft of ovarian tissue cryopreserved during childhood: Figure 1. Human Reproduction, 2015, 30, 2107-2109.	0.9	310
3	Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. Annals of Medicine, 2011, 43, 437-450.	3.8	309
4	ESHRE guideline: female fertility preservationâ€. Human Reproduction Open, 2020, 2020, hoaa052.	5.4	282
5	Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Human Reproduction, 2007, 22, 1837-1840.	0.9	254
6	Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelinesâ€. Annals of Oncology, 2020, 31, 1664-1678.	1.2	243
7	Orthotopic and heterotopic ovarian tissue transplantation. Human Reproduction Update, 2009, 15, 649-665.	10.8	234
8	Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: Case Report. Human Reproduction, 2006, 21, 2010-2014.	0.9	232
9	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of Clinical Oncology, 2016, 34, 2568-2574.	1.6	199
10	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 675-683.	7.7	169
11	Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Human Reproduction, 2018, 33, 1705-1714.	0.9	144
12	Premature ovarian aging in mice deficient for Gpr3. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8922-8926.	7.1	128
13	Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Human Reproduction, 2014, 29, 1931-1940.	0.9	125
14	Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial. Journal of Clinical Oncology, 2013, 31, 903-909.	1.6	108
15	Impact of various endocrine and paracrine factors on in vitro culture of preantral follicles in rodents. Reproduction, 2005, 130, 147-156.	2.6	93
16	Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e45-e56.	10.7	91
17	Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Annals of Oncology, 2018, 29, 237-243.	1.2	90
18	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treatment Reviews, 2019, 72, 65-77.	7.7	83

#	Article	IF	Citations
19	Follicle-stimulating hormone regulates expression and activity of epidermal growth factor receptor in the murine ovarian follicle. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16778-16783.	7.1	80
20	Effect of Insulin-Like Growth Factor-I During Preantral Follicular Culture on Steroidogenesis, In Vitro Oocyte Maturation, and Embryo Development in Mice1. Biology of Reproduction, 2004, 70, 1664-1669.	2.7	79
21	Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Human Reproduction, 2010, 25, 1581-1587.	0.9	79
22	Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reproductive Biology and Endocrinology, 2011, 9, 150.	3.3	77
23	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	2.2	75
24	Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reproductive BioMedicine Online, 2017, 34, 575-582.	2.4	70
25	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	1.6	70
26	Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Current Opinion in Oncology, 2017, 29, 243-252.	2.4	68
27	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. Cancer Treatment Reviews, 2017, 59, 61-70.	7.7	68
28	In-vitro maturation of human oocytes: before or after vitrification?. Journal of Assisted Reproduction and Genetics, 2012, 29, 507-512.	2.5	67
29	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. European Journal of Cancer, 2015, 51, 1490-1496.	2.8	64
30	Effect of preantral follicle isolation technique on in-vitro follicular growth, oocyte maturation and embryo development in mice. Human Reproduction, 2002, 17, 2152-2159.	0.9	63
31	Anonymity and secrecy options of recipient couples and donors, and ethnic origin influence in three types of oocyte donation. Human Reproduction, 2011, 26, 382-390.	0.9	63
32	Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft. Human Reproduction, 2010, 25, 1590-1591.	0.9	58
33	Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: A systematic review. Journal of Pediatric Surgery, 2019, 54, 2200-2209.	1.6	51
34	AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. Human Reproduction, 2015, 30, 1196-1202.	0.9	50
35	Preliminary experience of ovarian tissue cryopreservation procedure: alternatives, perspectives and feasibility. Reproductive BioMedicine Online, 2003, 7, 572-579.	2.4	49
36	Pregnancy outcome after oocyte donation in patients with Turner's syndrome and partial X monosomy. Human Reproduction, 2011, 26, 2061-2068.	0.9	49

#	Article	IF	Citations
37	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 574669.	2.8	48
38	Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Human Reproduction, 2015, 30, 2184-2189.	0.9	45
39	Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Human Reproduction Update, 2022, 28, 400-416.	10.8	43
40	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction, 2022, 37, 954-968.	0.9	41
41	Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-mÃ¼llerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. Frontiers in Oncology, 2019, 9, 575.	2.8	40
42	Anti-MÃ¼llerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update, 2022, 28, 417-434.	10.8	40
43	Interaction between PI3K/AKT and Hippo pathways during in vitro follicular activation and response to fragmentation and chemotherapy exposure using a mouse immature ovary model. Biology of Reproduction, 2020, 102, 717-729.	2.7	39
44	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e68-e80.	10.7	37
45	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. Journal of Clinical Oncology, 2021, 39, 2016-2024.	1.6	36
46	Implications of Nonphysiological Ovarian Primordial Follicle Activation for Fertility Preservation. Endocrine Reviews, 2020, 41, 847-872.	20.1	35
47	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. European Journal of Cancer, 2021, 144, 310-316.	2.8	34
48	Follicle-Stimulating Hormone Accelerates Mouse Oocyte Development In Vivo1. Biology of Reproduction, 2012, 87, 3, 1-11.	2.7	29
49	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	2.4	29
50	Does oocyte donation compared with autologous oocyte IVF pregnancies have a higher risk of preeclampsia?. Reproductive BioMedicine Online, 2017, 34, 11-18.	2.4	27
51	Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reproductive Biology and Endocrinology, 2019, 17, 3.	3.3	27
52	MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries. Scientific Reports, 2019, 9, 9636.	3.3	22
53	Challenges of fertility preservation in nonâ€oncological diseases. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 638-646.	2.8	22
54	Fertility, sexuality and cancer in young adult women. Current Opinion in Oncology, 2019, 31, 259-267.	2.4	20

#	Article	IF	Citations
55	Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-12.	1.3	18
56	First live birth after fertility preservation using vitrification of oocytes in a woman with mosaic Turner syndrome. Journal of Assisted Reproduction and Genetics, 2022, 39, 543-549.	2.5	18
57	Safety of Ovarian Tissue Autotransplantation for Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-6.	1.3	17
58	Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). Journal of Clinical Oncology, 2021, 39, 3251-3260.	1.6	17
59	Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model. PLoS ONE, 2015, 10, e0137164.	2.5	16
60	Risk of contamination of semen, vaginal secretions, follicular fluid and ovarian medulla with SARS-CoV-2 in patients undergoing ART. Human Reproduction, 2022, 37, 235-241.	0.9	16
61	Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice. Molecular Human Reproduction, 2018, 24, 221-232.	2.8	15
62	Oncofertility: Pharmacological Protection and Immature Testicular Tissue (ITT)-Based Strategies for Prepubertal and Adolescent Male Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 5223.	4.1	15
63	The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application. Human Reproduction Update, 2020, 26, 174-196.	10.8	15
64	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Review of Quality of Life in Cancer Care, 2017, 2, 47-59.	0.6	13
65	GnRH analogue for chemotherapy-induced ovarian damage: too early to say?. Fertility and Sterility, 2009, 92, e33.	1.0	12
66	Hardening of zona pellucida of mouse oocytes and embryos in vivo and in vitro. International Journal of Fertility and Women's Medicine, 1997, 42, 219-22.	0.4	12
67	Evaluation of quantitative polymerase chain reaction markers for the detection of breast cancer cells in ovarian tissue stored for fertility preservation. Fertility and Sterility, 2015, 104, 410-417.e4.	1.0	11
68	Ovarian tissue cryopreservation and transplantation in patients with central nervous system tumours. Human Reproduction, 2021, 36, 1296-1309.	0.9	11
69	OPTIONS TO PRESERVE FERTILITY BEFORE ONCOLOGICAL TREATMENT: CRYOPRESERVATION OF OVARIAN TISSUE AND ITS CLINICAL APPLICATION. Acta Clinica Belgica, 2006, 61, 259-263.	1.2	10
70	Ultrastructure and intercellular contact-mediated communication in cultured human early stage follicles exposed to mTORC1 inhibitor. Molecular Human Reproduction, 2019, 25, 706-716.	2.8	10
71	Viable Options for Fertility Preservation in Breast Cancer Patients: A Focus on Latin America. Revista De Investigacion Clinica, 2017, 69, 103-113.	0.4	9
72	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open, 2021, 6, 100300.	4.5	9

#	Article	IF	Citations
73	Assessment of ovarian reserve and fertility preservation strategies in children treated for cancer. Minerva Obstetrics and Gynecology, 2017, 69, 57-67.	1.0	8
74	Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model. Scientific Reports, 2022, 12, .	3.3	8
75	Fertility Preservation in Female Cancer Patients. Obstetrics and Gynecology International, 2012, 2012, 1-2.	1.3	7
76	Impact of ARTs on oncological outcomes in young breast cancer survivors. Human Reproduction, 2021, 36, 381-389.	0.9	7
77	Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. European Journal of Clinical Investigation, 2022, 52, e13779.	3.4	7
78	Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma. Lancet Oncology, The, 2018, 19, 1264-1266.	10.7	6
79	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. Oncotarget, 2019, 10, 926-929.	1.8	6
80	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 686625.	2.8	5
81	Unpredictable cases of complicated ovarian hyperstimulation in IVF. International Journal of Fertility and Women's Medicine, 1997, 42, 268-70.	0.4	5
82	Answer to Controversy: miR-10a Replacement Approaches Do Not Offer Protection against Chemotherapy-Induced Gonadotoxicity in Mouse Model. International Journal of Molecular Sciences, 2019, 20, 4958.	4.1	4
83	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. Scientific Reports, 2022, 12, 1658.	3.3	4
84	Nucleoside Analog Stavudine Depletes Mitochondrial DNA with No Organelle Loss in Mouse Oocytes. Current HIV Research, 2010, 8, 127-133.	0.5	3
85	Pregnancy Rate and Preservation of Cyclic Ovarian Function With Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapyâ€"Reply. JAMA Oncology, 2016, 2, 546.	7.1	3
86	Fertility preservation counselling for childhood cancer survivors. Lancet Oncology, The, 2020, 21, 329-330.	10.7	3
87	Response to â€˜Is it safe to perform a controlled ovarianÂstimulation for assisted reproduction in youngÂbreastÂcancer survivors?â€™. European Journal of Cancer, 2016, 54, 165-166.	2.8	2
88	Follicle Activation by Physical Methods and Clinical Applications. , 2022, , 263-278.		2
89	Reply to Z. Blumenfeld et al. Journal of Clinical Oncology, 2013, 31, 3722-3723.	1.6	1
90	Reply to M. Lambertini et al. Journal of Clinical Oncology, 2017, 35, 805-806.	1.6	1

#	Article	IF	Citations
91	The BCY3/BCC 2017 survey on physiciansâ€™ knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. European Journal of Cancer, 2018, 92, S22.	2.8	1
92	Use of GnRH Analogs for Prevention of Chemotherapy-Induced Gonadotoxicity. , 2021, , 171-181.		0
93	Anti-MÃ¼llerian hormone (AMH) as a marker of ovarian reserve and premature ovarian insufficiency (POI) in children and women with cancer: A systematic review.. Journal of Clinical Oncology, 2021, 39, e24057-e24057.	1.6	0
94	O-179 Safety of ovarian tissue cryopreservation and transplantation in patients with central nervous system cancers. Human Reproduction, 2021, 36, .	0.9	0
95	Overview of Fertility Preservation Approaches in Cancer Patients. , 2020, , 25-42.		0
96	A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients. Breast Cancer Research and Treatment, 2022, 192, 123-130.	2.5	0
97	Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Cancer Research, 2022, 82, PD5-05-PD5-05.	0.9	0
98	Reply: Risk of contamination with SARS-CoV-2 in ART. Human Reproduction, 2022, , .	0.9	0
99	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.. Journal of Clinical Oncology, 2022, 40, 12084-12084.	1.6	0
100	Methods of Ovarian Tissue Cryopreservation: Slow Freezing. , 2022, , 89-98.		0